Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab Versus Chemoimmunotherapy and Other Novel Combinations in First-Line Chronic Lymphocytic Leukemia in Canada

被引：1
|
作者：
Chatterjee, Anuja
Van de Wetering, Gijs
Goeree, Ron
Desbois, Anne Marie
Manzi, Patricia
Manzoor, Beenish S.
Owen, Carolyn
Sail, Kavita
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134596
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis
    Kongnakorn, Thitima
    Sterchele, James A.
    Salvador, Christopher G.
    Getsios, Denis
    Mwamburi, Mkaya
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2014, 6 : 141 - 149
  • [32] Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p
    Barnes, James, I
    Divi, Vasu
    Begaye, Adrian
    Wong, Russell
    Coutre, Steven
    Owens, Douglas K.
    Goldhaber-Fiebert, Jeremy D.
    BLOOD ADVANCES, 2018, 2 (15) : 1946 - 1956
  • [33] Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax plus Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors
    Ravelo, Arliene
    Patel, Achal
    To, Tu My
    Li, Sophia S.
    Huntington, Scott
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S345 - S345
  • [34] THE PHASE 2 CAPTIVATE STUDY: PRIMARY ANALYSIS OF A FIXED-DURATION COHORT FOLLOWING FIRST-LINE TREATMENT WITH IBRUTINIB PLUS VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
    Dela Rosa, Maria
    Anderson, Blanche
    Ninomoto, Joi
    Krigsfeld, Gabe
    Wierda, William
    Siddiqi, Tanya
    ONCOLOGY NURSING FORUM, 2022, 49 (02) : E55 - E56
  • [35] A UK Cost-Effectiveness Analysis Comparing First Line Treatment with Rituximab in Combination with Fludarabine and Cyclophosphamide Versus Fludarabine and Cyclophosphamide Alone in Chronic Lymphocytic Leukemia (CLL) Patients
    Papadakis, Konstantinos
    Oscier, David
    Carr, Emma S. C.
    Lewis, Gavin
    Aultman, Rick
    BLOOD, 2008, 112 (11) : 834 - 834
  • [36] Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
    Allan, John N.
    Flinn, Ian W.
    Siddiqi, Tanya
    Ghia, Paolo
    Tam, Constantine S.
    Kipps, Thomas J.
    Barr, Paul M.
    Camburn, Anna Elinder
    Tedeschi, Alessandra
    Badoux, Xavier C.
    Jacobs, Ryan
    Kuss, Bryone J.
    Trentin, Livio
    Zhou, Cathy
    Szoke, Anita
    Abbazio, Christopher
    Wierda, William G.
    CLINICAL CANCER RESEARCH, 2023, 29 (14) : 2593 - 2601
  • [37] Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax
    Jain, Nitin
    Croner, Lisa J.
    Allan, John N.
    Siddiqi, Tanya
    Tedeschi, Alessandra
    Badoux, Xavier C.
    Eckert, Karl
    Cheung, Leo W. K.
    Mukherjee, Anwesha
    Dean, James P.
    Szafer-Glusman, Edith
    Seymour, John F.
    CLINICAL CANCER RESEARCH, 2024, 30 (03) : 498 - 505
  • [38] 60-month data from iris used to update estimates of survival and cost-effectiveness of first-line imatinib in patients with chronic phase chronic myeloid leukemia
    Reed, S. D.
    Anstrom, K. J.
    Li, Y.
    Schulman, K. A.
    VALUE IN HEALTH, 2007, 10 (03) : A12 - A12
  • [39] First-Line Fixed-Duration Ibrutinib Plus Venetoclax ( Ibr plus Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study
    Moreno, Carol
    Munir, Talha
    Owen, Carolyn
    Follows, George
    Rivas, Jose-Angel Hernandez
    Benjamini, Ohad
    Janssens, Ann
    Levin, Mark-David
    Robak, Tadeusz
    Simkovic, Martin
    Voloshin, Sergey
    Vorobyev, Vladimir I.
    Yagci, Munci
    Ysebaert, Loic
    Qi, Qianya
    Smith, Emma
    Srinivasan, Srimathi
    Schuier, Natasha
    Baeten, Kurt
    Caces, Donne Bennett
    Niemann, Carsten Utoft
    Kater, Arnon P.
    BLOOD, 2023, 142
  • [40] Fixed-duration ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study
    Burger, J. A.
    Barr, P. M.
    Allan, J. N.
    Siddiqi, T.
    Wierda, W. G.
    Tam, C. S.
    Moreno, C.
    Tedeschi, A.
    Szafer-Glusman, E.
    Zhou, C.
    Abbazio, C.
    Dean, J. P.
    Szoke, A.
    Ghia, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 87 - 88
12345